| Literature DB >> 36047584 |
Junseob Yun1, Jungwon Lee1,2, Sungtae Kim1, Ki-Tae Koo1, Yang-Jo Seol1, Yong-Moo Lee3.
Abstract
PURPOSE: The role of hard-type crosslinked hyaluronic acid (HA) with particulate bone substitutes in bone regeneration for combined inlay-onlay grafts has not been fully investigated. We aimed to evaluate the effect of hard-type crosslinked HA used with bone substitute in terms of new bone formation and space maintenance.Entities:
Keywords: Bone regeneration; Bone substitute; Hyaluronic acid; Osteogenesis
Year: 2022 PMID: 36047584 PMCID: PMC9436643 DOI: 10.5051/jpis.2104700235
Source DB: PubMed Journal: J Periodontal Implant Sci ISSN: 2093-2278 Impact factor: 2.086
Figure 1(A) Timeline of the study. (B) Surgical procedure.
BCP: biphasic calcium phosphate.
Figure 2(A) Representative image of micro-computed tomography, including the control, BCP, and BCP/HA groups at 4 and 12 weeks after surgery. Red circles represent the cross section of the volume of interest. At 12 weeks, more new bone formation was observed than at 4 weeks. In the BCP/HA group, more space between particles is observed than in the other groups. This may have been caused by agglomerated undissolved hyaluronic acid. (B) Schematic diagram of the linear histomorphometric analysis. Green dotted line: H_pristine, yellow dotted line: H_augmented, blue dotted line: H_middle, vertical arrow: creeping distance, horizontal arrow: ingrowth distance.
BCP: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos, Suwon, Korea) + absorbable membrane (Collagen Membrane-P, Genoss), BCP/HA: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos) + hyaluronic acid (Monalisa, hard type, Genoss) + absorbable membrane (Collagen Membrane-P, Genoss), H_pristine: height of pristine bone, H_augmented: height of augmented bone, H_middle: height of bone in the midline.
Results of micro-computed tomography for the 3 groups
| Time | Group | n | BV/TV | BS/BV | BS/TV |
|---|---|---|---|---|---|
| 4 wk | Control | 4 | 7.37±1.95a) | 19.52±2.60a) | 1.43±0.34a) |
| BCP | 5 | 17.30±1.71b) | 60.27±3.84b) | 10.41±0.98b) | |
| BCP/HA | 5 | 7.22±0.43a) | 72.56±14.59b) | 5.20±0.82c) | |
| 0.011 | 0.011 | 0.003 | |||
| 12 wk | Control | 4 | 9.45±0.59a) | 16.21±1.13a) | 1.53±0.08a) |
| BCP | 5 | 15.48±3.13b) | 61.02±11.12b) | 9.18±0.95b) | |
| BCP/HA | 5 | 7.63±1.98a) | 68.39±15.20b) | 5.38±2.27c) | |
| 0.008 | 0.017 | 0.004 |
BCP: biphasic calcium phosphate (hydroxyapatite 60% + β- tricalcium phosphate 40%, Osteon III, Genos, Suwon, Korea) + absorbable membrane (Collagen Membrane-P, Genoss), BCP/HA: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos) + hyaluronic acid (Monalisa, hard type, Genoss) + absorbable membrane (Collagen Membrane-P, Genoss), BV/TV: bone volume/tissue volume, BS/BV: bone surface/bone volume, BS/TV: bone surface/tissue volume.
Different letters, a, b and c indicate statistical differences under the Bonferroni correction.
Figure 3Representative microscopic views. Masson trichome staining was used 4 and 12 weeks after surgery. (A-C) The control group at 4 weeks with original magnification of 2.0×, 9.0×, and 9.0×. New bone formation (arrow) is observed in the defect margin. (D-F) The BCP group at 4 weeks with original magnifications of 2.0×, 9.0×, and 9.0×. New bone formation (arrow) is observed above the superior border of the defect, between the bone particles, and under the membrane (arrowhead). In the middle area, bone particles are surrounded by connective tissue. (G-H) The BCP/HA group at 4 weeks with original magnifications of 2.0×, 9.0×, and 9.0×. Undissolved HA agglomerate is observed in the middle area of the defect. (J-L) Control group at 12 weeks with original magnifications of 2.0×, 9.0×, and 9.0×. (M-O) The BCP group at 12 weeks with original magnifications of 2.0×, 9.0×, and 9.0×. New bone formation was observed in the middle of the defect, between the bone particles. (P-O) The BCP/HA group at 12 weeks with original magnifications of 2.0×, 9.0×, and 9.0×. Arrow: new bone; Arrowhead: membrane.
BP: bone particle, CT: connective tissue, BCP: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos, Suwon, Korea) + absorbable membrane (Collagen Membrane-P, Genoss), BCP/HA: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos) + hyaluronic acid (Monalisa, hard type, Genoss) + absorbable membrane (Collagen Membrane-P, Genoss).
a)Undissolved HA.
Linear analysis for the 3 groups at 4 and 12 weeks
| Variable | Group | |||||
|---|---|---|---|---|---|---|
| Control | BCP | BCP/HA | ||||
| 4 wk | ||||||
| Length (µm) | ||||||
| H_pristine | 1,571.21±345.65 | 1,742.63±186.42 | 1,686.55±234.26 | 0.553 | ||
| H_augmented | 993.99±257.03a) | 2,867.33±421.42b) | 2,385.71±213.81b) | 0.008 | ||
| H_middle | 88.93±173.85a) | 2,437.18±967.41b) | 1,588.02±712.53b) | 0.009 | ||
| Creeping | 0.00±0.00a) | 520.42±111.53b) | 233.93±222.20a,b) | 0.009 | ||
| Ingrowth | 2,438.95±746.33a) | 2,411.07±993.56a) | 545.60±424.56b) | 0.011 | ||
| Ratio | ||||||
| H_augmented/H_pristine | 0.63±0.08a) | 1.64±0.13b) | 1.44±0.28b) | 0.013 | ||
| H_middle/H_pristine | 0.06±0.12a) | 1.38±0.49b) | 0.95±0.51b) | 0.014 | ||
| Creeping/H_pristine | 0.00±0.00a) | 0.30±0.08b) | 0.14±0.14a,b) | 0.012 | ||
| 12 wk | ||||||
| Length (µm) | ||||||
| H_pristine | 2,048.86±393.29 | 1,852.83±211.22 | 2,018.00±161.60 | 0.448 | ||
| H_augmented | 1,288.43±302.56a) | 2,581.19±217.06b) | 1,690.47±410.85a) | 0.007 | ||
| H_middle | 401.95±290.51a) | 2,391.14±669.56b) | 1,640.98±484.67b) | 0.010 | ||
| Creeping | 0.00±0.00a) | 566.95±246.21b) | 72.58±104.74a) | 0.005 | ||
| Ingrowth | 3,026.41±644.26a) | 4,101.20±993.65a) | 1,170.74±518.33b) | 0.006 | ||
| Ratio | ||||||
| H_augmented/H_pristine | 0.63±0.06a) | 1.41±0.22b) | 0.84±0.20a) | 0.006 | ||
| H_middle/H_pristine | 0.22±0.19a) | 1.31±0.41b) | 0.81±0.22a,b) | 0.011 | ||
| Creeping/H_pristine | 0.00±0.00a) | 0.32±0.18b) | 0.03±0.05a) | 0.005 | ||
H_pristine: height of pristine bone, H_augmented: height of augmented bone, H_middle: height of bone in the midline, BCP: biphasic calcium phosphate (hydroxyapatite 60% + β- tricalcium phosphate 40%, Osteon III, Genos, Suwon, Korea) + absorbable membrane (Collagen Membrane-P, Genoss), BCP/HA: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos) + hyaluronic acid (Monalisa, hard type, Genoss) + absorbable membrane (Collagen Membrane-P, Genoss).
Different letters, a and b indicate statistical differences under the Bonferroni correction.
Histomorphometric results for the 3 groups at 4 and 12 weeks
| Variable | Group | |||||
|---|---|---|---|---|---|---|
| Control | BCP | BCP/HA | ||||
| 4 wk | ||||||
| Area (mm2) | ||||||
| NB | 4.35±1.27 | 5.55±2.10 | 4.45±1.25 | 0.566 | ||
| CT | 12.95±3.89a) | 10.75±3.99a) | 7.17±0.83b) | 0.036 | ||
| GM | - | 22.35±4.62a) | 14.22±6.90b) | 0.005 | ||
| uHA | 0.00±0.00a) | 0.00±0.00a) | 6.01±3.96b) | 0.002 | ||
| Total | 17.30±3.82a) | 38.66±9.27b) | 31.85±7.30b) | 0.013 | ||
| 12 wk | ||||||
| Area (mm2) | ||||||
| NB | 5.69±2.07a,b) | 10.50±2.88b) | 4.28±0.97a) | 0.017 | ||
| CT | 14.10±1.39a) | 11.65±1.08b) | 9.29±2.89b) | 0.015 | ||
| GM | - | 15.37±4.55 | 11.99±3.79 | 0.222 | ||
| uHA | 0.00±0.00a) | 0.00±0.00a) | 7.82±12.41b) | 0.011 | ||
| Total | 26.53±2.41 | 37.52±5.60 | 32.77±13.62 | 0.087 | ||
BCP: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos, Suwon, Korea) + absorbable membrane (Collagen Membrane-P, Genoss), BCP/HA: biphasic calcium phosphate (hydroxyapatite 60% + β-tricalcium phosphate 40%, Osteon III, Genos) + hyaluronic acid (Monalisa, hard type, Genoss) + absorbable membrane (Collagen Membrane-P, Genoss), NB: newly formed bone, CT: connective tissue, GM: graft material, Total: total area of regenerated or augmented tissue in control and test groups, uHA: undissolved hyaluronic acid.